NW-3509a

DRUG2 trials

Sponsors

Newron Pharmaceuticals SPA

Conditions

Chronic SchizophreniaSchizophrenia

Phase 1

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

CompletedNCT01955564

Newron Pharmaceuticals SPASchizophrenia

Start: 2013-06-30End: 2015-02-28Updated: 2017-06-20

Phase 2

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

CompletedNCT02624167

Newron Pharmaceuticals SPAChronic Schizophrenia

Start: 2015-12-31End: 2017-01-31Updated: 2017-03-14